

**Efficacy of once daily darunavir/ritonavir 800/100 mg in
PI/r-experienced HIV-1 infected patients with
suppressed HIV-1 replication: the RADAR study**

Jade Ghosn, Aziza Chermak, Allal Houssaini, Gilles Peytavin, Sidonie Lambert-Niclot, Nicolas Eychenne, Laurence Slama, Anne Brunet, Claudine Duvivier, Alain Simon, et al.

► **To cite this version:**

Jade Ghosn, Aziza Chermak, Allal Houssaini, Gilles Peytavin, Sidonie Lambert-Niclot, et al.. Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study. Tenth International Congress on Drug Therapy in HIV Infection, Nov 2010, Glasgow, United Kingdom. BioMed Central, 13 (Suppl 4), pp.P41, 2010, Journal of the International AIDS Society. <10.1186/1758-2652-13-S4-P41>. <inserm-00668432>

HAL Id: inserm-00668432

<http://www.hal.inserm.fr/inserm-00668432>

Submitted on 9 Feb 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

POSTER PRESENTATION

Open Access

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study

J Ghoshn^{1*}, A Chermak², A Houssaini³, G Peytavin⁴, S Lambert-Niclot², N Eychenne⁴, L Slama⁵, A Brunet⁶, C Duvivier⁷, A Simon², AG Marcelin², P Flandre³, C Katlama²

From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010

Background

Once-daily darunavir/ritonavir 800/100 mg is licensed for first-line treatment and data are available in treatment-experienced patients with no resistance-associated mutations to darunavir. We designed an investigator study to evaluate the switch to once-daily darunavir/ritonavir 800/100 mg in treatment-experienced patients with suppressed HIV-1 replication on a twice-daily ritonavir-boosted protease-inhibitor (bid PI/r) containing regimen, i.e. in a setting where genotypic resistance test cannot be performed.

Methods

In this open-label, noncomparative, multicenter study, patients on a bid PI/r-containing triple combination, with suppressed viral replication, were switched to once-daily darunavir/r 800/100 mg containing triple combination. The primary endpoint was the proportion of patients with plasma HIV-RNA < 50 cp/ml 24 weeks after the switch. Detailed darunavir pharmacokinetic evaluation was performed at Week 4 (W4) and measurement of HIV-RNA in seminal plasma at baseline and W48 in a subset of patients.

Results

85 patients were enrolled. All had HIV-RNA < 50 cp/ml at screening with a median of 478 CD4/mm³ (range 40-1559) and pre-exposure to a median of 2 PI (1-5). 61

patients were currently on lopinavir/r, 18 on fosamprenavir/r, 4 on saquinavir/r and 2 on indinavir/r. At baseline, 15/16 patients had a seminal HIV-RNA < 100 cp/ml and 125 cp/ml for the remaining one. By intent-to-treat analysis (missing=failure), 78/85 patients (92%, CI95 [83;96]) maintained an HIV-RNA < 50 cp/ml at W24. 7 patients experienced protocol-defined treatment failure between baseline and W24: 2 had confirmed viral rebound (88 and 70 cp/ml), 1 discontinued study treatment at W4 for adverse event, 3 withdrew their consent and 1 was lost to follow-up. By on-treatment analysis, 78/80 patients (97%, CI95 [91;99]) maintained an HIV-RNA < 50 cp/ml at W24. At W4, the median area under the darunavir plasma concentration-time curve measured in 11 patients was 61 380 ng.h/ml (IQR 25-75% 42 094-97 313), darunavir median trough concentration 1340 ng/ml (907-1830) and darunavir half-life was 12.2 h (8.3-13.7). Tolerability of once-daily darunavir/r 800/100 mg was excellent.

Conclusion

In PI/r-experienced patients with suppressed viral replication on a bid PI/r-containing regimen, switching to once-daily darunavir/r 800/100 mg containing regimen was able to maintain suppression of viral replication and was safe in this setting where genotypic resistance test could not be performed.

Author details

¹AP-HP, Bicetre University Hospital, Internal Medicine and Infectious Diseases, Le Kremlin Bicetre, France. ²AP-HP, Pitie-Salpetriere University Hospital, Paris, France. ³Pierre and Marie Curie University, INSERM U-943, Paris, France. ⁴AP-

¹AP-HP, Bicetre University Hospital, Internal Medicine and Infectious Diseases, Le Kremlin Bicetre, France
Full list of author information is available at the end of the article

HP, Bichat-Claude Bernard University Hospital, Paris, France. ⁵AP-HP, Tenon University Hospital, Paris, France. ⁶AP-HP, Bicetre University Hospital, Le Kremlin Bicetre, France. ⁷AP-HP, Necker University Hospital, Paris, France.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-P41

Cite this article as: Ghosn *et al.*: Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):P41.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

